Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the U.S. biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings and broke news about the industry’s top companies. His stories appeared in The New York Times, Los Angeles Times, Boston Globe, and International Herald Tribune. Before that, from 2001 to 2006, his passionate coverage of biotechnology won many awards for The Seattle Times.
While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service.
Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke enjoys distance running, mountaineering, and fantasy baseball.
-
Cerus has struggled for years to convince regulators that its technology for ridding the nation’s blood supply of pathogens deserves a chance on the U.S. market. Now the Concord, CA-based biotech... Read more »
-
Emerald BioStructures, the contract research firm in Bainbridge Island, WA, said today it has formed a new collaboration with Boulder, CO-based SomaLogic. The deal calls for Emerald to provide its... Read more »
-
San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity. It’s Japan-based Takeda Pharmaceutical.
Under the terms of the deal... Read more »
-
Being a hospital CEO sounds like a mind-numbing, innovation-crushing job to me. I imagine days filled with insurance hassles, egotistical docs, malpractice lawyers, and boring meetings about saving on rubber gloves.... Read more »
-
Billions of dollars are being poured into R&D against cancer, by governments and pharma companies all over the world. I write about it pretty much every week on Xconomy. So it... Read more »
-
Five Prime Therapeutics is one of those companies built on the old school biotech business model. Take a cutting-edge scientific concept, mix in top scientists and big name venture backers, and... Read more »
-
One of the many companies in Boston taking a shot at developing a new class of therapies has gotten a second vote of confidence from investors. Cambridge, MA-based Anchor Therapeutics has... Read more »
-
The movement toward better/faster/cheaper gene sequencing dominated the Bay Area life sciences beat this week. Serious money is flowing into this industry.
—Pacific Biosciences lit a spark for gene sequencing... Read more »
-
Complete Genomics, the Mountain View, CA-based provider of low-cost gene sequencing, said today it has raised $39 million in a Series E round of venture financing. A new investor, Sands... Read more »
-
Kristina Burow of Arch Venture Partners was itching to tell me something back in mid-June when we met at her office in San Francisco’s Mission Bay district. It involved a... Read more »
-
We had some noteworthy personnel moves, a big real estate deal, and some legal battling on the biotech beat this week.
—The Institute for Systems Biology made it clear early this... Read more »
-
Leroy Hood is a walker. Now the biotech pioneer is going to be able to walk around in a very productive way.
Once Hood and the rest of the Institute for... Read more »
-
The worst kept secret in the local biotech real estate market is now official: The Institute for Systems Biology is moving to Seattle’s South Lake Union neighborhood, into the modern building... Read more »
-
BioMarin Pharmaceutical (NASDAQ: BMRN), the Novato, CA-based maker of drugs for rare diseases, said it has agreed to acquire Milwaukee, WI-based ZyStor Therapeutics for $22 million upfront, plus another $93... Read more »
-
Quark Pharmaceuticals, the Fremont, CA-based developer of RNA interference drugs, said today it has struck a deal to provide Novartis with an option on an exclusive worldwide license to a new... Read more »
-
There’s a changing of the guard happening over at one of the historic addresses in Seattle biotech—1100 Olive Way. This former car dealership, which for more than 15 years was home... Read more »
-
Calypso Medical Technologies, the Seattle-based maker of technology to pinpoint radiation therapy to reduce side effects, is announcing today that Siemens Healthcare has agreed to distribute its system throughout Europe.... Read more »
-
Life Technologies just made a very aggressive move in the ultra-competitive world of fast and cheap gene sequencing.
The Carlsbad, CA-based maker of life sciences instruments (NASDAQ: LIFE) said today... Read more »
-
One of the fastest-growing companies in the Northwest has little to do with high-tech, biotech, or cleantech. Tacoma, WA-based Sound Physicians owes its rapid rise to an innovative form of healthcare... Read more »
-
The people at Genentech have created an enduring perception about antibodies, which says these Y-shaped protein drugs are really good at specifically targeting cancer cells. When I was at Bloomberg News... Read more »
